bluebird bio Inc. (BLUE) announced after the close Tuesday that the National Institutes of Health Recombinant DNA Advisory Committee's completed its public review of the HGB-208 pediatric study protocol for bluebird bio's LentiGlobin BB305 product candidate in beta-thalassemia major. The committee recommended to delay initiation of the study in the United States for one to two years. The stock is now down 8.64 on 12K shares.
bluebird bio declined during the first hour of trade Tuesday, but recovered some ground in the early afternoon. Shares finished down by 1.98 at $186.63. The stock closed near the middle of a 3-week range at the highs of the year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.